论文部分内容阅读
目的研究应用多西他赛加吡柔比星行乳腺癌新辅助化疗的疗效评价及影响因素。方法检测87例乳腺癌新辅助化疗患者术前穿刺和术后病理学标本,做免疫组化检测ER、PR、CerbB-2,行新辅助化疗,分析获得病理学完全缓解(pCR)与患者年龄、病期、化疗周期数及ER、PR、CerbB-2表达的相关性。结果ER(+)的患者获得pCR(6.1%)比ER(-)的患者(29.0%)低(P<0.01);PR(+)的患者获得pCR(11.1%)比PR(-)的患者(29.2%)低(P<0.05);CerbB-2过表达患者pCR率(20.0%)高于非CerbB-2过表达者(15.0%),但是差异无显著性(P=0.8452),年龄、病期、化疗周期数与pCR无明显相关性。结论ER、PR阴性表达的患者对多西他赛加吡柔比星治疗反应性好。
Objective To study the efficacy and influencing factors of neoadjuvant chemotherapy for the treatment of breast cancer with docetaxel plus pirarubicin. Methods 87 patients with neoadjuvant chemotherapy for breast cancer were examined with preoperative puncture and postoperative pathological specimens. Immunohistochemistry was used to detect ER, PR and CerbB-2 in neoadjuvant chemotherapy. The complete pathologic response (pCR) and age , The duration of disease, the number of cycles of chemotherapy and the expression of ER, PR and CerbB-2. Results Patients with ER (+) had lower pCR (6.1%) than patients with ER (-) (29.0%) (P <0.01); patients with PR (+) had pCR (29.2%) was lower than that of CerbB-2 overexpression (P <0.05). The pCR rate of CerbB-2 overexpression was higher than that of non-CerbB-2 overexpression (15.0% The duration of disease and the number of chemotherapy cycles had no significant correlation with pCR. Conclusions Patients with negative expression of ER and PR have good response to docetaxel plus docetaxel.